Trials / Unknown
UnknownNCT03416231
Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
A Study of Combined Treatment of Apatinib With Docetaxel as Post Second-line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Affiliated Hospital of North Sichuan Medical College · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the effectiveness and safety of apatinib combined with docetaxel in NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression. |
| DRUG | Docetaxel | Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4\~6 cycles. |
Timeline
- Start date
- 2016-11-30
- Primary completion
- 2019-01-01
- Completion
- 2020-01-01
- First posted
- 2018-01-31
- Last updated
- 2018-01-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03416231. Inclusion in this directory is not an endorsement.